Back

Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.

A New Wave of Progress in The Treatment of Multiple Myeloma: Translating Evidence to Clinical Practice

Episodes

Specialty:

All

Year:

All

EP. 1: Evaluating Frontline Treatment Strategies in NDMM: The DETERMINATION Trial

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

June 29th 2022

Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.

EP. 2: Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

June 29th 2022

Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.

EP. 3: Transplant-Eligible NDMM: Assessing Response to Therapy and Role of MRD Negativity

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

July 6th 2022

Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.

EP. 4: Transplant-Eligible NDMM: Optimal Duration of Treatment

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

July 6th 2022

Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

EP. 5: Role of Maintenance Therapy and Key Takeaways in Transplant-Eligible NDMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

July 14th 2022

Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.

EP. 6: Transplant-Ineligible NDMM: MAIA Study and SWOG-S0777 Studies

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

July 14th 2022

An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.

EP. 7: Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.

EP. 8: RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

EP. 9: BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.

EP. 10: Teclistamab in RRMM: Patient Selection and Combining Therapies

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.

EP. 11: Talquetamab, Cevostamab and Elranatamab in RRMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 4th 2022

After reviewing other novel bispecific antibodies including talquetamab, cevostamab, and elranatamab in RRMM, panelists consider how these agents compare and might be selected for specific patients.

EP. 12: Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 4th 2022

Shared insight on the adverse event profiles of novel bispecific antibody therapies, with specific focus on how CRS can be adequately managed by the health care team.

EP. 13: Selection and Sequencing Of Bispecific Antibodies in RRMM and Key Takeaways

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 11th 2022

Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.

EP. 14: CAR T-Cell Therapy: CARTITUDE-1 Study and the Role of Cilta-Cel in RRMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 11th 2022

Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.

EP. 15: CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 18th 2022

Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

EP. 16: CAR T-Cell Therapy in RRMM: Adverse Event Management

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 18th 2022

Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.

EP. 17: Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 25th 2022

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

EP. 18: Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 25th 2022

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

A New Wave of Progress in The Treatment of Multiple Myeloma: Translating Evidence to Clinical Practice

Episodes

EP. 1: Evaluating Frontline Treatment Strategies in NDMM: The DETERMINATION Trial

EP. 2: Quadruplet Therapy in Transplant-Eligible NDMM: Implications of GRIFFIN and MASTER Studies

EP. 3: Transplant-Eligible NDMM: Assessing Response to Therapy and Role of MRD Negativity

EP. 4: Transplant-Eligible NDMM: Optimal Duration of Treatment

EP. 5: Role of Maintenance Therapy and Key Takeaways in Transplant-Eligible NDMM

EP. 6: Transplant-Ineligible NDMM: MAIA Study and SWOG-S0777 Studies

EP. 7: Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

EP. 8: RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

EP. 9: BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

EP. 10: Teclistamab in RRMM: Patient Selection and Combining Therapies

EP. 11: Talquetamab, Cevostamab and Elranatamab in RRMM

EP. 12: Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management

EP. 13: Selection and Sequencing Of Bispecific Antibodies in RRMM and Key Takeaways

EP. 14: CAR T-Cell Therapy: CARTITUDE-1 Study and the Role of Cilta-Cel in RRMM

EP. 15: CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM

EP. 16: CAR T-Cell Therapy in RRMM: Adverse Event Management

EP. 17: Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

EP. 18: Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL